USA flag logo/image

An Official Website of the United States Government

Decision Support System for Predicting outcome of ER+ breast cancers

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2011 / SBIR
Agency Tracking Number:
R43EB015199
Solicitation Year:
2011
Solicitation Topic Code:
NIBIB
Solicitation Number:
PA10-050
Small Business Information
IBRIS, INC.
307 MARGARET CT SOUTH PLAINFIELD, NJ 07080-2342
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2011
Title: Decision Support System for Predicting outcome of ER+ breast cancers
Agency: HHS
Contract: 1R43EB015199-01
Award Amount: $207,067.00
 

Abstract:

DESCRIPTION (provided by applicant): We propose an alternative, inexpensive means for identifying the subset of women with ER+ breast cancer for whom hormonal therapy alone is sufficient, and adjuvant chemotherapy is not required. Our novel approach uses computer vision and machine learning techniques to extract information from digitized histological sections of breast tissue (e.g. graphical and morphological arrangement of nuclei, lymphocytes, textural appearance, and tubule density), yielding a continuous image-based risk score (IbRiS) from zero to one that predicts the risk of recurrence. By choosing the appropriate cutoff value, IbRiS can be used to stratify ER+ patients into two classes: low and high risk. A low risk identifies those women who would respond well to hormonal therapy alone. Of the 120,000 women annually diagnosed with estrogen receptor positive (ER+) breast cancer in the US, the vast majority will be considered at high risk of having distant recurrence (metastasis) within 10 years. Undercurrent National Comprehensive Cancer Network (NCCN) guidelines, these women will be advised to receive adjuvant chemotherapy in addition to standard hormonal treatment (e.g. tamoxifen). However, 85% of these women will not benefit from chemotherapy, andyet will still incur its deleterious side-effects. The only non-investigational tool to help better determine which women should receive tamoxifen alone is the Oncotype Dx molecular assay, which is now widely used by medical oncologists. Oncotype Dx is able to correctly reclassify (as low-risk) 50% of those women with ER+ cancers that have been classified as high-risk (or intermediate-risk) by the NCCN guidelines, obviating their need for chemotherapy. However, Oncotype Dx is inaccessible to the majority of women in the US (and worldwide) because of its high cost ( 4500), and requirement that the tissue samples be sent to specialized remote facilities. Consequently, there is clearly a market need for a lower-priced assay capable of reaching a wider audience. The specific aims of this proposal are as follows: 1) develop an image-based risk score (IbRiS) for predicting the subset of women with ER+ breast cancer that wil respond wel without chemotherapy and 2) evaluate IbRiS performance in predicting recurrence over an independent set of ER+ breast cancers treated with tamoxifen alone. IbRiS has several key advantages over molecular assays. First, it requires no disruption of the current clinical protocol since the necessary tissue samples are already collectedduring routine pathological examinations. Second, IbRiS has a zero cost-of-goods sold, and thus could serve as either a lower-priced alternative to a molecular assay or as a quantitative triage, determining which patients should be administered the more expensive molecular test. Finally, since IbRiS only requires a digital slide scanner (i.e. no specialized facility is necessary), its footprint could extend worldwide (via the internet). PUBLIC HEALTH RELEVANCE: Every year tens of thousands of womenin the US with estrogen receptor positive (ER+) breast cancer are treated with chemotherapy, though only a few thousand will benefit from it. In this proposal we will develop an image-based risk score (IbRiS) to predict which women with ER+ breast cancer do not require chemotherapy. This test will provide an economical alternative to the far more expensive gene-expression based assays currently in use.

Principal Investigator:

Dave Harding
214-681-5133
dave.harding@ibrisinc.com

Business Contact:

James Monaco
214-681-5133
jpmonaco@rci.rutgers.edu
Small Business Information at Submission:

IBRIS, INC.
307 MARGARET CT SOUTH PLAINFIELD, NJ 07080-2342

EIN/Tax ID: 127287673
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No